PERSPECTIVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 USD | -1.25% |
|
+5.33% | +293.03% |
Chart calendar Perspective Therapeutics, Inc.
7e6e77faceebf487bbcbc5a9.N-yp0QkdZkmzEv-VpoOkVXosm5CdHLg0C2brW8fUkrw.ALjnlExeAhDwe4zY6OXAPQNIw9GveOABOz-0Yqm8-Y0BguaAX2oIHPx0xw~0173067d71c8fa0fdaf56adefd67c254
Upcoming events on Perspective Therapeutics, Inc.
Past events on Perspective Therapeutics, Inc.
| 11/04/2024 13:35 | Jefferies Radiopharma Innovation Summit |
| 09/04/2024 19:40 | Goldman Sachs Third Annual Healthruption Conference |
| 28/03/2024 11:30 | Q4 2023 Earnings Release |
| 18/03/2024 14:00 | Analyst Day |
| 01/03/2024 19:30 | B. Riley Securities Radiopharma Day - Panel |
| 01/03/2024 18:45 | B. Riley Securities Radiopharma Day - Panel |
| 01/03/2024 15:00 | B. Riley Securities Radiopharma Day - Panel |
| 28/02/2024 16:00 | Investor Meeting |
| 14/02/2024 16:20 | Oppenheimer Healthcare Life Sciences Conference |
| 11/01/2024 20:00 | JPMorgan Healthcare Conference |
| 08/01/2024 18:30 | Biotech Showcase |
| 07/01/2024 | BIO Partnering JPM Conference |
| 07/01/2024 22:30 | BFC Global HealthCare BD & Investment Conference |
| 07/01/2024 17:15 | BFC Global HealthCare BD & Investment Conference - Panel |
| 14/11/2023 21:25 | Q3 2023 Earnings Release |
| 05/10/2023 | Annual General Meeting |
| 03/10/2023 | North American Neuroendocrine Tumor Society Symposium - Phase 1/2 Trial of Pb-212-VMT |
| 03/10/2023 | North American Neuroendocrine Tumor Society Symposium - Phase 1 Trial of Pb-212-VMT |
| 30/09/2023 | American Society for Radiation Oncology Conference |
| 12/09/2023 08:45 | European Association of Nuclear Medicine Congress - Abstract Number: OP-673 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 7,31 7,41 -1.35% | 9,68 10,1 -4.08% | 10,1 10,0 0.2% | 3,55 | 1,43 8,46 -83.04% | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -5,07 -5,10 0.63% | -2,87 -3,10 7.45% | -2,87 -2,80 -2.64% | 0,00 | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -5,25 -5,62 6.45% | -3,55 -3,40 -4.28% | -3,45 -3,29 -4.62% | 0,00 | -40,9 -43,4 5.6% | -49,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -5,14 -5,53 6.92% | -3,45 -3,39 -1.77% | -3,39 -3,30 -2.64% | 0,00 | -40,1 -43,0 6.64% | -46,7 |
|
Net income Million USD | Released Forecast Spread | -5,16 -5,53 6.72% | -3,46 -3,39 -2.1% | -3,39 -3,25 -4.3% | 0,00 | -46,5 -37,7 -23.33% | -48,1 |
|
EPS USD | Released Forecast Spread | -0,08 -0,09 5.88% | -0,05 -0,05 -11.11% | -0,03 -0,03 -12.49% | -0,05 | -0,17 -0,14 -21.43% | -0,09 |
| Announcement Date | 24/09/19 | 17/09/20 | 21/09/21 | 01/05/23 | 28/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,71 2,70 0.37% | 2,06 | 2,09 2,61 -20% | 1,91 2,20 -13.23% | -4,90 2,12 -331.06% | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -0,92 -0,80 -14.5% | |||||||||
|
EBIT Million USD | Released Forecast Spread | -1,09 -0,91 -20.2% | -11,4 -7,66 -48.56% | -10,5 -10,3 -2.57% | -7,81 -10,2 23.79% | -14,8 | |||||
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -1,06 -0,90 -17.89% | -11,1 -7,65 -45.21% | -10,4 -10,3 -0.92% | -7,77 -10,7 27.11% | -10,7 | -10,8 | -10,9 | -11,7 | -14,7 | |
|
Net income Million USD | Released Forecast Spread | -1,06 -0,91 -16.94% | -11,1 -7,65 -45.16% | -10,4 -10,3 -0.89% | -24,7 -10,7 -131.35% | -12,7 | -11,5 | -10,9 | -11,7 | -14,7 | |
|
EPS USD | Released Forecast Spread | -0,01 -0,01 0% | 0,00 | -0,04 -0,03 -33.33% | -0,04 -0,04 0% | -0,09 -0,04 -125% | -0,03 | -0,03 | -0,03 | -0,03 | |
| Announcement Date | 21/09/21 | 15/05/23 | 11/08/23 | 14/11/23 | 28/03/24 | - | - | - | - | - |
More events
Past sector events for Perspective Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CATX Stock
- Calendar Perspective Therapeutics, Inc.
